GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » OncoSec Medical Inc (FRA:ONMA) » Definitions » Cyclically Adjusted Price-to-FCF

OncoSec Medical (FRA:ONMA) Cyclically Adjusted Price-to-FCF : (As of Jun. 05, 2024)


View and export this data going back to 2015. Start your Free Trial

What is OncoSec Medical Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


OncoSec Medical Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for OncoSec Medical's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OncoSec Medical Cyclically Adjusted Price-to-FCF Chart

OncoSec Medical Annual Data
Trend Jul13 Jul14 Jul15 Jul16 Jul17 Jul18 Jul19 Jul20 Jul21 Jul22
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

OncoSec Medical Quarterly Data
Apr18 Jul18 Oct18 Jan19 Apr19 Jul19 Oct19 Jan20 Apr20 Jul20 Oct20 Jan21 Apr21 Jul21 Oct21 Jan22 Apr22 Jul22 Oct22 Jan23
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of OncoSec Medical's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, OncoSec Medical's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


OncoSec Medical's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, OncoSec Medical's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where OncoSec Medical's Cyclically Adjusted Price-to-FCF falls into.



OncoSec Medical Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

OncoSec Medical's Cyclically Adjusted FCF per Share for the quarter that ended in Jan. 2023 is calculated as:

For example, OncoSec Medical's adjusted Free Cash Flow per Share data for the three months ended in Jan. 2023 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Jan. 2023 (Change)*Current CPI (Jan. 2023)
=-2.371/126.2230*126.2230
=-2.371

Current CPI (Jan. 2023) = 126.2230.

OncoSec Medical Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201304 -46.630 98.107 -59.993
201307 -36.815 98.557 -47.150
201310 -45.879 98.536 -58.771
201401 -33.375 98.692 -42.685
201404 -39.085 100.023 -49.323
201407 -42.811 100.520 -53.758
201410 -54.429 100.176 -68.582
201501 -62.536 98.604 -80.053
201504 -86.786 99.824 -109.737
201507 -85.016 100.691 -106.574
201510 -68.343 100.346 -85.967
201601 -59.829 99.957 -75.550
201604 -55.234 100.947 -69.064
201607 -48.663 101.524 -60.502
201610 -46.826 101.988 -57.953
201701 -39.822 102.456 -49.059
201704 -44.415 103.167 -54.341
201707 -41.361 103.278 -50.550
201710 -42.802 104.070 -51.913
201801 -31.842 104.578 -38.433
201804 -20.416 105.708 -24.378
201807 -22.100 106.324 -26.236
201810 -23.494 106.695 -27.794
201901 -19.821 106.200 -23.558
201904 -22.571 107.818 -26.424
201907 -16.259 108.250 -18.959
201910 -15.186 108.577 -17.654
202001 -13.766 108.841 -15.964
202004 -7.569 108.173 -8.832
202007 -7.794 109.318 -8.999
202010 -6.802 109.861 -7.815
202101 -6.837 110.364 -7.819
202104 -6.305 112.673 -7.063
202107 -4.007 115.183 -4.391
202110 -4.781 116.696 -5.171
202201 -4.953 118.619 -5.270
202204 -2.765 121.978 -2.861
202207 -3.798 125.002 -3.835
202210 -3.476 125.734 -3.490
202301 -2.371 126.223 -2.371

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


OncoSec Medical  (FRA:ONMA) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


OncoSec Medical Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of OncoSec Medical's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


OncoSec Medical (FRA:ONMA) Business Description

Industry
Traded in Other Exchanges
Address
24 North Main Street, Pennington, NJ, USA, 08534
OncoSec Medical Inc is a healthcare sector company. It is focused on designing, developing and commercializing gene therapies, therapeutics, and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The company's lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple-negative breast cancer.

OncoSec Medical (FRA:ONMA) Headlines

No Headlines